Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.

Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S, Yamada-Okabe H, Okada Y, Sasano H.

Int J Mol Sci. 2018 Feb 18;19(2). pii: E609. doi: 10.3390/ijms19020609.

2.

Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues.

Narumi S, Miki Y, Hata S, Ebina M, Saito M, Mori K, Kobayashi M, Suzuki T, Iwabuchi E, Sato I, Maemondo M, Endo C, Inoue A, Kondo T, Yamada-Okabe H, Ichinose M, Sasano H.

Int J Biol Markers. 2015 May 26;30(2):e234-42. doi: 10.5301/jbm.5000131.

PMID:
25634032
3.

Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma.

Iida S, Miki Y, Suzuki T, Mori K, Saito M, Niikawa H, Kondo T, Yamada-Okabe H, Sasano H.

Anticancer Res. 2014 Apr;34(4):1821-7.

PMID:
24692715
4.

An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.

Nihira K, Miki Y, Iida S, Narumi S, Ono K, Iwabuchi E, Ise K, Mori K, Saito M, Ebina M, Sato I, Maemondo M, Yamada-Okabe H, Kondo T, Sasano H.

J Pathol. 2014 Oct;234(2):277-88. doi: 10.1002/path.4354. Epub 2014 Aug 18.

PMID:
24687913
5.

Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.

Harada T, Ozaki S, Oda A, Tsuji D, Ikegame A, Iwasa M, Udaka K, Fujii S, Nakamura S, Miki H, Kagawa K, Kuroda Y, Kawai S, Itoh K, Yamada-Okabe H, Matsumoto T, Abe M.

PLoS One. 2013 Dec 26;8(12):e83905. doi: 10.1371/journal.pone.0083905. eCollection 2013.

6.

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.

Kobayashi M, Miki Y, Ebina M, Abe K, Mori K, Narumi S, Suzuki T, Sato I, Maemondo M, Endo C, Inoue A, Kumamoto H, Kondo T, Yamada-Okabe H, Nukiwa T, Sasano H.

Br J Cancer. 2012 Nov 6;107(10):1745-53. doi: 10.1038/bjc.2012.422. Epub 2012 Oct 25.

7.

LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution.

Kobayashi S, Yamada-Okabe H, Suzuki M, Natori O, Kato A, Matsubara K, Jau Chen Y, Yamazaki M, Funahashi S, Yoshida K, Hashimoto E, Watanabe Y, Mutoh H, Ashihara M, Kato C, Watanabe T, Yoshikubo T, Tamaoki N, Ochiya T, Kuroda M, Levine AJ, Yamazaki T.

Stem Cells. 2012 Dec;30(12):2631-44. doi: 10.1002/stem.1257.

8.

Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors.

Ikegame A, Ozaki S, Tsuji D, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, Kagawa K, Takeuchi K, Abe M, Watanabe K, Hiasa M, Kimura N, Kikuchi Y, Sakamoto A, Habu K, Endo M, Itoh K, Yamada-Okabe H, Matsumoto T.

Leukemia. 2012 Sep;26(9):2124-34. doi: 10.1038/leu.2012.78. Epub 2012 Mar 20.

PMID:
22430632
9.

A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway.

Sagawa M, Shimizu T, Fukushima N, Kinoshita Y, Ohizumi I, Uno S, Kikuchi Y, Ikeda Y, Yamada-Okabe H, Kizaki M.

Cancer Sci. 2011 Jun;102(6):1208-15. doi: 10.1111/j.1349-7006.2011.01925.x. Epub 2011 May 3.

10.

Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.

Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K, Orita T, Tsuchiya M, Hattori K, Yamada-Okabe H.

Anticancer Drugs. 2010 Nov;21(10):907-16. doi: 10.1097/CAD.0b013e32833f5d68.

PMID:
20847643
11.

Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells.

Takahashi S, Yamada-Okabe H, Hamada K, Ohta S, Kawase T, Yoshida K, Toda M.

J Neurooncol. 2011 Jun;103(2):267-76. doi: 10.1007/s11060-010-0398-z. Epub 2010 Sep 16.

PMID:
20845060
12.

Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.

Miki Y, Suzuki T, Abe K, Suzuki S, Niikawa H, Iida S, Hata S, Akahira J, Mori K, Evans DB, Kondo T, Yamada-Okabe H, Sasano H.

Cancer Res. 2010 Aug 15;70(16):6659-69. doi: 10.1158/0008-5472.CAN-09-4653.

13.

A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.

Ishiguro T, Kawai S, Habu K, Sugimoto M, Shiraiwa H, Iijima S, Ozaki S, Matsumoto T, Yamada-Okabe H.

Cancer Sci. 2010 Oct;101(10):2227-33. doi: 10.1111/j.1349-7006.2010.01663.x. Epub 2010 Aug 5.

14.

Similar changes of hypothalamic feeding-regulating peptides mRNAs and plasma leptin levels in PTHrP-, LIF-secreting tumors-induced cachectic rats and adjuvant arthritic rats.

Suzuki H, Hashimoto H, Kawasaki M, Watanabe M, Otsubo H, Ishikura T, Fujihara H, Ohnishi H, Onuma E, Yamada-Okabe H, Takuwa Y, Ogata E, Nakamura T, Ueta Y.

Int J Cancer. 2011 May 1;128(9):2215-23. doi: 10.1002/ijc.25535.

15.

Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models.

Yoneya T, Taniguchi K, Nakamura R, Tsunenari T, Ohizumi I, Kanbe Y, Morikawa K, Kaiho S, Yamada-Okabe H.

Anticancer Res. 2010 Mar;30(3):873-8.

PMID:
20393009
16.

Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells.

Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K, Nguyen ST, Miki Y, Iimura T, Himeno A, Akashi T, Yamada-Okabe H, Ogata E, Yamaguchi A.

Am J Pathol. 2010 Feb;176(2):968-80. doi: 10.2353/ajpath.2010.090299. Epub 2009 Dec 24.

17.

A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.

Endo M, Miwa M, Ura M, Tanimura H, Taniguchi K, Miyazaki Y, Ohwada J, Tsukazaki M, Niizuma S, Murata T, Ozawa S, Suda H, Ogawa K, Nanba E, Nagao S, Shimma N, Yamada-Okabe H.

Cancer Chemother Pharmacol. 2010 Jan;65(2):363-71. doi: 10.1007/s00280-009-1042-5.

PMID:
19495753
18.

Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.

Yoneya T, Tsunenari T, Taniguchi K, Kanbe Y, Morikawa K, Yamada-Okabe H, Lee YH, Lee MH, Kwon LS.

Oncol Rep. 2009 Mar;21(3):747-55.

PMID:
19212635
19.

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, Kodama T, Tsuchiya M, Yamada-Okabe H.

Cancer Res. 2008 Dec 1;68(23):9832-8. doi: 10.1158/0008-5472.CAN-08-1973.

20.

Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.

Kawai S, Azuma Y, Fujii E, Furugaki K, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H.

Cancer Sci. 2008 Dec;99(12):2461-6. doi: 10.1111/j.1349-7006.2008.00968.x. Epub 2008 Nov 20.

21.

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.

Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M.

Biochem Biophys Res Commun. 2009 Jan 9;378(2):279-84. doi: 10.1016/j.bbrc.2008.11.033. Epub 2008 Nov 18.

PMID:
19022220
22.

A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma.

Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Sano F, Baba M, Kondo K, Nakaigawa N, Kishida T, Nagashima Y, Yamada-Okabe H, Kubota Y.

Int J Cancer. 2008 Sep 1;123(5):1126-32. doi: 10.1002/ijc.23641.

23.

A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy.

Somura H, Iizuka N, Tamesa T, Sakamoto K, Hamaguchi T, Tsunedomi R, Yamada-Okabe H, Sawamura M, Eramoto M, Miyamoto T, Hamamoto Y, Oka M.

Oncol Rep. 2008 Feb;19(2):489-95.

PMID:
18202799
24.

Identification of a neuron-specific human gene, KIAA1110, that is a guanine nucleotide exchange factor for ARF1.

Hattori Y, Ohta S, Hamada K, Yamada-Okabe H, Kanemura Y, Matsuzaki Y, Okano H, Kawakami Y, Toda M.

Biochem Biophys Res Commun. 2007 Dec 28;364(4):737-42. Epub 2007 Oct 15.

PMID:
17981261
25.

Involvement of cyclooxygenase-2 in the tumor site-dependent production of parathyroid hormone-related protein in colon 26 carcinoma.

Saito H, Inagaki Y, Tsunenari T, Ura M, Mizuno H, Fujimoto-Ouchi K, Onuma E, Sato K, Ogata E, Yamada-Okabe H.

Cancer Sci. 2007 Oct;98(10):1563-9. Epub 2007 Jul 23.

26.

Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.

Azuma Y, Ishikawa Y, Kawai S, Tsunenari T, Tsunoda H, Igawa T, Iida S, Nanami M, Suzuki M, Irie RF, Tsuchiya M, Yamada-Okabe H.

Clin Cancer Res. 2007 May 1;13(9):2745-50. Erratum in: Clin Cancer Res. 2007 Jul 1;13(13):4029-31.

27.

Crystal structure of uridine-diphospho-N-acetylglucosamine pyrophosphorylase from Candida albicans and catalytic reaction mechanism.

Maruyama D, Nishitani Y, Nonaka T, Kita A, Fukami TA, Mio T, Yamada-Okabe H, Yamada-Okabe T, Miki K.

J Biol Chem. 2007 Jun 8;282(23):17221-30. Epub 2007 Mar 28.

28.

Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.

Uno S, Kinoshita Y, Azuma Y, Tsunenari T, Yoshimura Y, Iida S, Kikuchi Y, Yamada-Okabe H, Fukushima N.

Oncol Rep. 2007 May;17(5):1189-94.

PMID:
17390064
29.

A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.

Sekimoto E, Ozaki S, Ohshima T, Shibata H, Hashimoto T, Abe M, Kimura N, Hattori K, Kawai S, Kinoshita Y, Yamada-Okabe H, Tsuchiya M, Matsumoto T.

Cancer Res. 2007 Feb 1;67(3):1184-92.

30.

Parathyroid hormone-related protein induces cachectic syndromes without directly modulating the expression of hypothalamic feeding-regulating peptides.

Hashimoto H, Azuma Y, Kawasaki M, Fujihara H, Onuma E, Yamada-Okabe H, Takuwa Y, Ogata E, Ueta Y.

Clin Cancer Res. 2007 Jan 1;13(1):292-8.

31.

Purification, crystallization and preliminary X-ray diffraction studies of UDP-N-acetylglucosamine pyrophosphorylase from Candida albicans.

Maruyama D, Nishitani Y, Nonaka T, Kita A, Fukami TA, Mio T, Yamada-Okabe H, Yamada-Okabe T, Miki K.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Dec 1;62(Pt 12):1206-8. Epub 2006 Nov 4.

32.

Identification of ID2 associated with invasion of hepatitis C virus-related hepatocellular carcinoma by gene expression profile.

Tsunedomi R, Iizuka N, Yamada-Okabe H, Tamesa T, Okada T, Sakamoto K, Takashima M, Hamaguchi T, Miyamoto T, Uchimura S, Hamamoto Y, Yamada M, Oka M.

Int J Oncol. 2006 Dec;29(6):1445-51.

PMID:
17088983
33.

Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia.

Sato H, Yazawa T, Suzuki T, Shimoyamada H, Okudela K, Ikeda M, Hamada K, Yamada-Okabe H, Yao M, Kubota Y, Takahashi T, Kamma H, Kitamura H.

Am J Pathol. 2006 Nov;169(5):1550-66.

34.

Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus.

Iizuka N, Tsunedomi R, Tamesa T, Okada T, Sakamoto K, Hamaguchi T, Yamada-Okabe H, Miyamoto T, Uchimura S, Hamamoto Y, Oka M.

J Cancer Res Clin Oncol. 2006 Jul;132(7):473-81. Epub 2006 Apr 25.

PMID:
16703398
35.

Crystal structures of N-acetylglucosamine-phosphate mutase, a member of the alpha-D-phosphohexomutase superfamily, and its substrate and product complexes.

Nishitani Y, Maruyama D, Nonaka T, Kita A, Fukami TA, Mio T, Yamada-Okabe H, Yamada-Okabe T, Miki K.

J Biol Chem. 2006 Jul 14;281(28):19740-7. Epub 2006 May 1.

36.

Esophageal squamous cell carcinomas with distinct invasive depth show different gene expression profiles associated with lymph node metastasis.

Sato T, Iizuka N, Hamamoto Y, Yoshino S, Abe T, Takeda S, Uchimura S, Miyamoto T, Sei F, Hamada K, Yamada-Okabe H, Oka M.

Int J Oncol. 2006 May;28(5):1043-55.

PMID:
16596220
37.

Purification, crystallization and preliminary X-ray diffraction studies of N-acetylglucosamine-phosphate mutase from Candida albicans.

Nishitani Y, Maruyama D, Nonaka T, Kita A, Fukami TA, Mio T, Yamada-Okabe H, Yamada-Okabe T, Miki K.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Apr 1;62(Pt 4):419-21. Epub 2006 Mar 25.

38.

Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.

Kawai S, Koishihara Y, Iida S, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H.

Leuk Res. 2006 Aug;30(8):949-56. Epub 2006 Feb 13.

PMID:
16473407
39.

Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.

Kawai S, Yoshimura Y, Iida S, Kinoshita Y, Koishihara Y, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H.

Oncol Rep. 2006 Feb;15(2):361-7.

PMID:
16391855
40.

Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.

Saito H, Tsunenari T, Onuma E, Sato K, Ogata E, Yamada-Okabe H.

Anticancer Res. 2005 Nov-Dec;25(6B):3817-23. Erratum in: Anticancer Res. 2006 Jan-Feb;26(1a):445.

41.

Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma.

Tsunedomi R, Iizuka N, Hamamoto Y, Uchimura S, Miyamoto T, Tamesa T, Okada T, Takemoto N, Takashima M, Sakamoto K, Hamada K, Yamada-Okabe H, Oka M.

Int J Oncol. 2005 Sep;27(3):661-7.

PMID:
16077914
42.

Identification of a novel, orally bioavailable estrogen receptor downregulator.

Yoneya T, Taniguchi K, Tsunenari T, Saito H, Kanbe Y, Morikawa K, Yamada-Okabe H.

Anticancer Drugs. 2005 Aug;16(7):751-6.

PMID:
16027525
43.

Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.

Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E.

Clin Cancer Res. 2005 Jun 1;11(11):4198-203.

45.

Imbalance in expression levels of insulin-like growth factor 2 and H19 transcripts linked to progression of hepatocellular carcinoma.

Iizuka N, Oka M, Tamesa T, Hamamoto Y, Yamada-Okabe H.

Anticancer Res. 2004 Nov-Dec;24(6):4085-9.

46.

Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma.

Kikuchi Y, Uno S, Kinoshita Y, Yoshimura Y, Iida S, Wakahara Y, Tsuchiya M, Yamada-Okabe H, Fukushima N.

Leuk Res. 2005 Apr;29(4):445-50. Epub 2004 Dec 18.

PMID:
15725479
47.

Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival.

Hasumi H, Ishiguro H, Nakamura M, Sugiura S, Osada Y, Miyoshi Y, Fujinami K, Yao M, Hamada K, Yamada-Okabe H, Kubota Y, Uemura H.

Int J Cancer. 2005 Jul 20;115(6):911-6.

48.

Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma.

Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Sakamoto K, Hamada K, Ishitsuka H, Miyamoto T, Uchimura S, Hamamoto Y.

FEBS Lett. 2005 Feb 14;579(5):1089-100.

49.

Sex-based molecular profiling of hepatitis C virus-related hepatocellular carcinoma.

Takemoto N, Iizuka N, Yamada-Okabe H, Hamada K, Tamesa T, Okada T, Hashimoto K, Sakamoto K, Takashima M, Miyamoto T, Uchimura S, Hamamoto Y, Oka M.

Int J Oncol. 2005 Mar;26(3):673-8.

PMID:
15703822
50.

Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma.

Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, Tamesa T, Takemoto N, Hashimoto K, Sakamoto K, Miyamoto T, Uchimura S, Hamamoto Y, Oka M.

Int J Cancer. 2005 Jun 10;115(2):231-40.

Supplemental Content

Loading ...
Support Center